Clearmind Medicine Forms a Data and Safety Monitoring Board to Oversee its First-in-Human Clinical Trial

2 years ago

Tel Aviv, Israel / Vancouver, Canada, April 27, 2023 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (NASDAQ: CMND) (CSE: CMND), (FSE:…

Tavros Therapeutics and OpenBench Expand Strategic Collaboration for Small Molecule Drug Discovery

2 years ago

Multi-target collaboration leverages Tavros’ proprietary functional genomic discovery program and OpenBench’s screening platform Partnership streamlines drug development for novel cancer…

Outlook Therapeutics® to Present at the H.C. Wainwright BioConnect Investor Conference

2 years ago

Russ Trenary, President and Chief Executive Officer and Glen Olsheim, Executive Director, Commercial Excellence of Outlook Therapeutics to participate in…

Coherus and Junshi Biosciences Announce Toripalimab Studies to be Presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting

2 years ago

SHANGHAI, China and REDWOOD CITY, Calif., April 27, 2023 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences”, HKEX:…

Ceapro Inc. Appoints Michel Regnier as Senior Vice President, Technical Operations

2 years ago

Executive function to oversee Edmonton site technical operations with implementation of Pilot Unit for Pressurized Gas eXpanded (PGX) Technology as…

Ocean Biomedical (NASDAQ: OCEA) Announces New Glioblastoma Results Validating Profound Tumor Suppression with Anti-Chi3L1 Antibody

2 years ago

Results published in peer-reviewed Cancer Research share novel insights into Chi3L1’s role in modulating Glioma stem cells and reinforces the…

Comera Life Sciences to Participate in Four Upcoming Conferences

2 years ago

WOBURN, Mass., April 27, 2023 (GLOBE NEWSWIRE) -- Comera Life Sciences Holdings, Inc. (Nasdaq: CMRA) (“Company” or “Comera”), a life…

Akoya Biosciences Marks Milestone Achievement with Shipment of 1,000th Spatial Biology Instrument

2 years ago

MARLBOROUGH, Mass., April 27, 2023 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced…

Certara Customers Received 90 Percent of US FDA Novel Drug Approvals for 9th Consecutive Year

2 years ago

Asserts Certara’s leadership in advancing the development and approval of new drugs for patientsPRINCETON, N.J., April 27, 2023 (GLOBE NEWSWIRE)…

Galectin Therapeutics to Participate in the H.C. Wainwright BioConnect Investment Conference May 2, 2023

2 years ago

NORCROSS, Ga., April 27, 2023 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target…